NO2729147T3 - - Google Patents

Info

Publication number
NO2729147T3
NO2729147T3 NO12741268A NO12741268A NO2729147T3 NO 2729147 T3 NO2729147 T3 NO 2729147T3 NO 12741268 A NO12741268 A NO 12741268A NO 12741268 A NO12741268 A NO 12741268A NO 2729147 T3 NO2729147 T3 NO 2729147T3
Authority
NO
Norway
Application number
NO12741268A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2729147T3 publication Critical patent/NO2729147T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO12741268A 2011-07-04 2012-07-04 NO2729147T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161504265P 2011-07-04 2011-07-04

Publications (1)

Publication Number Publication Date
NO2729147T3 true NO2729147T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-02-03

Family

ID=46601758

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12741268A NO2729147T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2011-07-04 2012-07-04

Country Status (6)

Country Link
US (2) US9782397B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2729147B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2729147T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2672099T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO2729147T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013004766A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240034866A (ko) 2015-06-06 2024-03-14 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
EP3463315B1 (en) * 2016-06-02 2023-06-14 ADS Therapeutics LLC Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
CA3071377C (en) 2017-01-09 2021-11-30 Kathleen E. Clarence-Smith Compositions and methods for improving muscle weakness in patients suffering from myasthenia gravis and other myasthenic syndromes
WO2019023175A1 (en) * 2017-07-25 2019-01-31 Gt Biopharma, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE AND NEOSTIGMINE AND AN ANTAGONIST NK-1 FOR THE TREATMENT OF SEVERE MYASTHENIA
JP2021514976A (ja) * 2018-02-26 2021-06-17 オスペダーレ・サン・ラッファエーレ・エッセエッレエッレ 眼痛の治療における使用のためのnk−1拮抗薬
US20210030761A1 (en) * 2018-03-28 2021-02-04 The Regents Of The University Of Colorado, A Body Corporate Treatment and prevention of alpha herpes virus infection
US20230134843A1 (en) * 2020-03-11 2023-05-04 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919205A (en) 1972-07-17 1975-11-11 Squibb & Sons Inc Dithiocarbonylthioacetyl cephalosporin derivatives
US5166331A (en) 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
FR2654725B1 (fr) 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5420297A (en) 1990-10-24 1995-05-30 Fujisawa Pharmaceutical Co., Ltd. Peptides having substance P antagonistic activity
FR2676055B1 (fr) 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH0733386B2 (ja) 1991-05-31 1995-04-12 フアイザー・インコーポレイテツド キヌクリジン誘導体
GB9113219D0 (en) 1991-06-19 1991-08-07 Fujisawa Pharmaceutical Co Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same
JPH06509332A (ja) 1991-07-05 1994-10-20 メルク シヤープ エンド ドーム リミテツド 芳香族化合物、それらを含む医薬組成物、及び治療におけるそれらの使用
US5552534A (en) 1991-08-22 1996-09-03 The Trustees Of The University Of Pennsylvania Non-Peptide peptidomimetics
EP0916346A3 (en) 1991-09-20 2000-12-06 Glaxo Group Limited NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
GB9200535D0 (en) 1992-01-10 1992-02-26 Fujisawa Pharmaceutical Co New compound
WO1993017032A1 (en) 1992-02-24 1993-09-02 The Trustees Of The University Of Pennsylvania Techniques and intermediates for preparing non-peptide peptidomimetics
FR2689889B1 (fr) 1992-04-10 1994-06-10 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, et leur preparation.
TW241258B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-04-15 1995-02-21 Takeda Pharm Industry Co Ltd
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5719147A (en) 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
IL111002A (en) 1993-09-22 1998-09-24 Glaxo Group Ltd Piperidine derivatives their preparation and pharmaceutical compositions containing them
US6403577B1 (en) 1993-11-17 2002-06-11 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
IL111730A (en) 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
FR2718136B1 (fr) 1994-03-29 1996-06-21 Sanofi Sa Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant.
CA2198382A1 (en) 1994-09-30 1996-04-11 Novartis Ag 1-acyl-4-aliphatylaminopiperidine compounds
BR9607335A (pt) 1995-02-22 1997-11-25 Novartis Ag Compostos 1-aril-2-acrilamino-etano e seu uso como neuroquinina especialmente antogonistas de neuroquinina 1
GB9505692D0 (en) 1995-03-21 1995-05-10 Glaxo Group Ltd Chemical compounds
US5886011A (en) 1995-03-27 1999-03-23 Hisamitsu Pharmaceutical Co., Inc. Piperidine derivatives as substance P antagonists
DE19519245C2 (de) 1995-04-14 2003-04-30 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
GB9510600D0 (en) 1995-05-25 1995-07-19 Fujisawa Pharmaceutical Co Piperazine derivatives
TW382017B (en) 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
DE19608665A1 (de) 1996-03-06 1997-09-11 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
GB9625843D0 (en) 1996-12-12 1997-01-29 Merck & Co Inc Phenyl spiroethercycloalkyl tachykinn receptor antagonists
AU5239898A (en) 1996-10-25 1998-05-15 Merck & Co., Inc. Phenyl spiroethercycloalkyl tachykinin receptor antagonists
US5929094A (en) 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
GB9700597D0 (en) 1997-01-14 1997-03-05 Sandoz Pharma Uk Organic compounds
JPH10259184A (ja) 1997-03-18 1998-09-29 Takeda Chem Ind Ltd 三環性複素環化合物の製造法
ZA985765B (en) 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.
HUP0003548A3 (en) 1997-08-06 2002-04-29 Lilly Co Eli 2-acylaminopropanamines as tachykinin receptor antagonists and pharmaceutical compositions containing the same
TW426667B (en) 1997-11-19 2001-03-21 Pfizer Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
US6291465B1 (en) 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
CO5150225A1 (es) 1999-03-19 2002-04-29 Merck Sharp & Dohme Derivados del tetrahidropirano y su uso como agentes terapeuticos
GB9907571D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Compounds
TR200103229T2 (tr) 1999-05-10 2002-04-22 Acordis Industrial Fibers Gmbh Filaman oluşturan poliesterler ve kopoliesterler ve bunların üretilmesi için bir işlem
JP3229294B2 (ja) 1999-06-04 2001-11-19 キヤノン販売株式会社 被成膜面の改質方法及び半導体装置の製造方法
EP1219619B1 (en) 1999-10-07 2004-08-11 Hisamitsu Pharmaceutical Co. Inc. 3-amino-2-phenylpiperidine derivatives as substance p antagonists
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
ATE400563T1 (de) 2000-04-06 2008-07-15 Astrazeneca Ab Neue neurokinin-antagonisten zum gebrauch als arzneimittel
ATE308513T1 (de) 2000-04-06 2005-11-15 Naphthamid-neurokinin antagonisten zur verwendung als medikamente
GB0012240D0 (en) 2000-05-19 2000-07-12 Merck Sharp & Dohme Therapeutic agents
CN1327997A (zh) 2000-06-12 2001-12-26 上海博德基因开发有限公司 一种新的多肽——Ras GTP酶激活蛋白9.57和编码这种多肽的多核苷酸
DE10036818A1 (de) 2000-07-28 2002-02-07 Solvay Pharm Gmbh Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten
PE20020444A1 (es) 2000-09-22 2002-06-14 Merck & Co Inc Antagonistas de receptores de taquiquinina zwitterionica
SE0003476D0 (sv) 2000-09-28 2000-09-28 Astrazeneca Ab Compounds
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US6642226B2 (en) 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
GB0108595D0 (en) 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
GB0114867D0 (en) 2001-06-18 2001-08-08 Merck Sharp & Dohme Therapeutic agents
GB0119797D0 (en) 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
EP1295599A1 (en) 2001-09-21 2003-03-26 Boehringer Ingelheim International GmbH Method for the treatment of prevention of atopic dermatitis
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
ATE427310T1 (de) 2002-01-18 2009-04-15 Kyorin Seiyaku Kk Kondensierte bicyclische pyrimidinderivate
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
JP2005522436A (ja) 2002-02-08 2005-07-28 グラクソ グループ リミテッド ピペリジルカルボキシアミド誘導体またはそのタキキニン介在疾患の治療における使用
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
JP2004002334A (ja) 2002-03-25 2004-01-08 Tanabe Seiyaku Co Ltd 医薬組成物
NZ535886A (en) 2002-04-26 2007-07-27 Lilly Co Eli Triazole derivatives as tachykinin receptor antagonists
GB0215392D0 (en) 2002-07-03 2002-08-14 Glaxo Group Ltd Chemical compounds
WO2004005256A2 (en) 2002-07-03 2004-01-15 Glaxo Group Limited Substituted 4-phenyl-piperidin-amides as tachykinin antagonists and serotonin reptake inhibitors
GB0217068D0 (en) 2002-07-23 2002-08-28 Merck Sharp & Dohme Therapeutic agents
GB0220953D0 (en) 2002-09-10 2002-10-23 Novartis Ag Organic compounds
GB0310724D0 (en) 2003-05-09 2003-06-11 Glaxo Group Ltd Chemical compounds
WO2005019225A1 (ja) 2003-08-21 2005-03-03 Kyorin Pharmaceutical Co., Ltd. Nk1受容体拮抗作用を有する化合物の製造方法及びその製造中間体
TWI341198B (en) 2004-01-27 2011-05-01 Merck Sharp & Dohme Hydroisoindoline tachykinin receptor antagonists
US8108430B2 (en) 2004-04-30 2012-01-31 Microsoft Corporation Carousel control for metadata navigation and assignment
GB0412865D0 (en) 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds
US20070293492A1 (en) 2004-12-03 2007-12-20 Devita Robert J Quinoline Tachykinin Receptor Antagonists
US20080039494A1 (en) 2004-12-03 2008-02-14 Jianming Bao 8-Phenyl-5,6,7,8-Hydroquinoline Tachykinin Receptor Antagonists
WO2006065711A2 (en) 2004-12-14 2006-06-22 Merck & Co., Inc. Octahydropyrano[3,4-c]pyrrole tachykinin receptor antagonists
US7354922B2 (en) 2004-12-14 2008-04-08 Schering Corporation Bridged ring NK1 antagonists
WO2006106727A1 (ja) 2005-03-31 2006-10-12 Nippon Zoki Pharmaceutical Co., Ltd. ベンジルオキシプロピルアミン誘導体
US20090048248A1 (en) 2005-12-22 2009-02-19 Devita Robert J Octahydropyrano[3,4-C]Pyrrole Tachykinin Receptor Antagonists
WO2007074491A1 (en) 2005-12-28 2007-07-05 Universita Degli Studi Di Siena HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS
JP2007277231A (ja) 2006-03-16 2007-10-25 Tanabe Seiyaku Co Ltd 医薬組成物
US20090286777A1 (en) 2006-05-15 2009-11-19 Jianming Bao 5,6,Fused Pyrrolidine Compounds Useful as Tachykinin Receptor Antagonists
CA2667543A1 (en) 2006-10-26 2008-05-02 Boehringer Ingelheim International Gmbh New pharmaceutical combinations for treatment of respiratory and gastrointestinal disorders
JP2008239618A (ja) 2007-02-28 2008-10-09 Mitsubishi Tanabe Pharma Corp 医薬組成物
CA2690737A1 (en) 2007-06-22 2008-12-31 Merck Sharp & Dohme Corp. 6.5-pyrrolopiperidine tachykinin receptor antagonists
PL2260029T3 (pl) * 2008-02-26 2015-03-31 Sandoz Ag Otrzymywanie pochodnych morfoliny
US20100098772A1 (en) 2008-10-21 2010-04-22 Allergan, Inc. Drug delivery systems and methods for treating neovascularization
ES2559475T3 (es) 2009-11-18 2016-02-12 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos de origen central
KR102166277B1 (ko) 2013-04-12 2020-10-15 삼성전자주식회사 무선 통신 네트워크를 이용한 운전 지원 방법 및 장치와 그 시스템
US11915196B2 (en) 2019-05-23 2024-02-27 Capital One Services, Llc Self-service lender portal

Also Published As

Publication number Publication date
US20180021327A1 (en) 2018-01-25
US20140128395A1 (en) 2014-05-08
ES2672099T3 (es) 2018-06-12
EP2729147B1 (en) 2017-09-06
US9782397B2 (en) 2017-10-10
WO2013004766A1 (en) 2013-01-10
EP2729147A1 (en) 2014-05-14
DK2729147T3 (en) 2017-12-18

Similar Documents

Publication Publication Date Title
BR122020015314A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR122020014038A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013031251A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013027245A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013024383A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013026905A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013027830A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013026744A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013027452A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013024365A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013028733A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013027121A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP2016009466A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013031556A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013024588A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013026790A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013032366A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013032380A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013032377A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013027836A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013026895A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013027761A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013032392A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013025487A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013027871A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)